CN103113216B - 萘普生钠晶体化合物、药物组合物及其制备方法 - Google Patents
萘普生钠晶体化合物、药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN103113216B CN103113216B CN201310086891.2A CN201310086891A CN103113216B CN 103113216 B CN103113216 B CN 103113216B CN 201310086891 A CN201310086891 A CN 201310086891A CN 103113216 B CN103113216 B CN 103113216B
- Authority
- CN
- China
- Prior art keywords
- naproxen sodium
- preparation
- naproxen
- sodium crystal
- crystal compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 title claims abstract description 67
- 229960003940 naproxen sodium Drugs 0.000 title claims abstract description 66
- 150000001875 compounds Chemical class 0.000 title claims abstract description 13
- 239000013078 crystal Substances 0.000 title abstract description 32
- 238000002360 preparation method Methods 0.000 title abstract description 23
- 239000000203 mixture Substances 0.000 title abstract description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- 238000002347 injection Methods 0.000 abstract description 14
- 239000007924 injection Substances 0.000 abstract description 14
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 239000007787 solid Substances 0.000 description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- 238000003756 stirring Methods 0.000 description 14
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 13
- 229960002009 naproxen Drugs 0.000 description 13
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000008227 sterile water for injection Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000005262 decarbonization Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940072359 anaprox Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
重量 | 溶剂体积 | 溶解情况 | 结论 | |
市售萘普生钠 | 1002.13 mg | 5 ml | 未完全溶解 | 不易溶 |
萘普生钠晶体 | 1022.24 mg | 3 ml | 完全溶解 | 易溶 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310086891.2A CN103113216B (zh) | 2013-03-18 | 2013-03-18 | 萘普生钠晶体化合物、药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310086891.2A CN103113216B (zh) | 2013-03-18 | 2013-03-18 | 萘普生钠晶体化合物、药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103113216A CN103113216A (zh) | 2013-05-22 |
CN103113216B true CN103113216B (zh) | 2014-12-10 |
Family
ID=48411632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310086891.2A Active CN103113216B (zh) | 2013-03-18 | 2013-03-18 | 萘普生钠晶体化合物、药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103113216B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104784125B (zh) * | 2015-04-14 | 2017-10-03 | 海南皇隆制药股份有限公司 | 一种注射用萘普生钠冻干粉针制剂及其制备方法 |
-
2013
- 2013-03-18 CN CN201310086891.2A patent/CN103113216B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103113216A (zh) | 2013-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102659818B (zh) | 一种盐酸头孢替安晶体化合物及其制备方法及含该化合物的药物组合物 | |
CN102924483B (zh) | 一种头孢他啶晶体化合物、其制备方法及其无菌混合粉形式的药物组合物 | |
CN102512380B (zh) | 一种以奥美拉唑钠为活性成分的冻干粉针剂及其制备方法 | |
CN102875574A (zh) | 头孢曲松钠晶型及其制备方法 | |
CN103833626A (zh) | 西达本胺的晶型及其制备方法与应用 | |
CN103965116A (zh) | 半5-氟胞嘧啶盐、其制备方法及应用 | |
CN102643255B (zh) | 一种炎琥宁化合物 | |
CN102276533B (zh) | 一种新的奥扎格雷钠化合物及其药物组合物 | |
CN103113216B (zh) | 萘普生钠晶体化合物、药物组合物及其制备方法 | |
CN104447541A (zh) | 博舒替尼化合物 | |
CN104650034A (zh) | 一种稳定的阿西替尼化合物 | |
CN102557918B (zh) | 一种布洛芬钠化合物及其制法 | |
CN102977101A (zh) | 多尼培南一水合物、其药物组合物、其制备方法和用途 | |
CN103070834B (zh) | 含有埃索美拉唑的冻干粉针 | |
CN104922080A (zh) | 治疗消化***疾病的药物艾普拉唑钠冻干粉针剂组合物 | |
CN103191051B (zh) | 一种奈拉滨注射液组合物及其制备方法 | |
CN102746272B (zh) | 一种埃索美拉唑钠多晶型物及其制备方法和应用 | |
CN102846563B (zh) | 一种培美曲塞二钠注射用组合物及其制备方法 | |
CN104447542A (zh) | 博舒替尼一水合物及其制备方法 | |
CN103058999A (zh) | 一种新型泮托拉唑钠化合物及其药物组合物 | |
CN104650086A (zh) | 盐酸帕纳替尼化合物 | |
CN102846561A (zh) | 一种供注射用的奥扎格雷钠药物组合物 | |
CN104045598B (zh) | 一种含芳胺结构的硫脲类化合物及其制备方法和应用 | |
CN101607968A (zh) | 长春氟宁盐、其制备方法及其药物组合物 | |
CN102746273A (zh) | 一种埃索美拉唑钠多晶型物及其在注射用药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130522 Assignee: SHANDONG PKU HIGH-TECH HUATAI PHARMACEUTICAL Co.,Ltd. Assignor: Ning Hui Contract record no.: 2014370000212 Denomination of invention: Naproxen sodium crystal compound, medical composition and preparation method thereof Granted publication date: 20141210 License type: Common License Record date: 20141226 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240423 Address after: Room 202, East Building C, Headquarters Center, No. 23 Guangfu East Street, Houtang Community, Jiangbei Street, Dongyang City, Jinhua City, Zhejiang Province, 322100 Patentee after: Zhejiang Zhongyan Pharmaceutical Technology Co.,Ltd. Country or region after: China Address before: Room 202, Study Abroad Building, No. 129 Fuzhou North Road, Shibei District, Qingdao City, Shandong Province, 266034 Patentee before: Ning Hui Country or region before: China |